TY - JOUR AU - Wimsatt, Jeffrey AU - Villers, Meghan AU - Thomas, Laurel AU - Kamarec, Stacey AU - Montgomery, Caitlin AU - Yeung, Leo W. Y. AU - Hu, Yanqing AU - Innes, Kim PY - 2016 DA - 2016/12/08 TI - Oral perfluorooctane sulfonate (PFOS) lessens tumor development in the APCmin mouse model of spontaneous familial adenomatous polyposis JO - BMC Cancer SP - 942 VL - 16 IS - 1 AB - Colorectal cancer is the second most common cause of cancer deaths for both men and women, and the third most common cause of cancer in the U.S. Toxicity of current chemotherapeutic agents for colorectal cancer, and emergence of drug resistance underscore the need to develop new, potentially less toxic alternatives. Our recent cross-sectional study in a large Appalachian population, showed a strong, inverse, dose–response association of serum perfluorooctane sulfonate (PFOS) levels to prevalent colorectal cancer, suggesting PFOS may have therapeutic potential in the prevention and/or treatment of colorectal cancer. In these preliminary studies using a mouse model of familial colorectal cancer, the APCmin mouse, and exposures comparable to those reported in human populations, we assess the efficacy of PFOS for reducing tumor burden, and evaluate potential dose–response effects. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-016-2861-5 DO - 10.1186/s12885-016-2861-5 ID - Wimsatt2016 ER -